Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target

Cell(2021)10.1016/j.cell.2021.09.006Source: DataRank Database

In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target is a research paper published in Cell (2021). On theSindex it has a DataRank of 0. It has been cited 198 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access198 citations

Download PDF

Cite:

Linked data & code

geo gen cellosaurus uniprot

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 9.11)OA: greenTopics (66)IDs (PubMed, PMC, OpenAlex)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (22)

Collin Tokheim ORCID,Shengqing Gu ORCID,Binbin Wang ORCID,Qin Tang ORCID,Yihao Li ORCID

Live enrichment

PubMed:34582788 PMC:PMC9136996 OpenAlex:https://openalex.org/W3111243436

National Institutes of Health

Grant: R01CA234018

Breast Cancer Research Foundation

Grant: BCRF-20-019

Breast Cancer Research Foundation

Grant: BCRF-20-100

Damon Runyon Cancer Research Foundation

Grant: DRQ-04-20

Dana-Farber Cancer Institute

Grant: 2.0

Sanofi

Bristol-Myers Squibb

Novartis

Sara Elizabeth O'Brien Trust

Takeda Pharmaceuticals U.S.A.

FWCI

9.11

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9136996

publisherhttps://api.elsevier.com/content/article/PII:S0092867421010539?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867421010539?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.cell.2021.09.006

Fields of Study

Protein Degradation and InhibitorsHIV Research and TreatmentCAR-T cell therapy researchAnimalsCCAAT-Enhancer-Binding Protein-deltaCRISPR-Associated Protein 9Cell Line, TumorChemokinesChemotaxisClustered Regularly Interspaced Short Palindromic RepeatsDisease Models, AnimalGene LibraryHumansImmune EvasionImmunotherapyMacrophagesMice, Inbred BALB CMice, Inbred C57BLNeoplasmsNuclear ProteinsProteolysisSubstrate SpecificityTriple Negative Breast NeoplasmsUbiquitin-Protein LigasesMice

MeSH Terms

CRISPR-Associated Protein 9AnimalsChemotaxisDisease Models, AnimalHumansImmunotherapyMacrophagesMice, Inbred BALB CMice, Inbred C57BLNeoplasmsNuclear ProteinsSubstrate SpecificityGene LibraryChemokinesUbiquitin-Protein LigasesCell Line, TumorMiceCCAAT-Enhancer-Binding Protein-deltaImmune EvasionProteolysisClustered Regularly Interspaced Short Palindromic RepeatsTriple Negative Breast Neoplasms

Keywords

BiologyCRISPRCancer immunotherapyUbiquitin ligaseIn vivoCancer researchGenome editingImmunotherapyCell biologyComputational biologyCancerGeneticsUbiquitinGeneCOP1E3 ubiquitin ligaseTriple-negative Breast CancerC/ebpδCrispr Screening

Sustainable Development Goals

SDG 0: Good health and well-being